Gilead Sciences stock gains as HIV prevention licensing deal expands
Published on 09/16/2026 at 21:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences, Inc. stock (ISIN US3755581036) is trading close to the upper end of its 52-week range, with the Nasdaq-listed shares around USD 148 as of September 16, 2026, supported by fresh news on expanded access for its once-yearly HIV prevention drug lenacapavir.
HIV prevention licensing deal lifts sentiment
According to Investing.com on September 16, 2026, Gilead Sciences announced it has expanded six royalty-free voluntary licensing agreements to include its investigational once-yearly lenacapavir for HIV prevention, broadening access across 120 countries with high HIV infection rates.
The expanded licensing framework targets primarily low- and lower-middle-income regions, where HIV prevention remains a critical unmet need, and is aligned with the company’s global access strategy for lenacapavir as the drug progresses through phase 3 trials with potential market introduction around 2028, as highlighted by GuruFocus.
Stock trades near top of 52-week range
Per Nasdaq price data cited by MEXC, Gilead Sciences stock was quoted at USD 148.42 on the Nasdaq on September 16, 2026 at 3:35 p.m., up 1.45% or USD 2.12 compared with a prior closing price of USD 146.30.
In the same source, the 52-week high for Gilead Sciences stock is reported at USD 157.29, while the 52-week low stands at USD 108.46, meaning the current price of around USD 148.42 is roughly USD 8.87 below the recent high and USD 39.96 above the low, underlining that the shares are trading in the upper part of their yearly range.
According to MEXC, Gilead Sciences had a market capitalization of USD 181.54 billion as of September 16, 2026, with intraday trading volume reported around 883,540 shares, signaling robust liquidity in the stock.
Recent 2026 earnings beats and profitability picture
For fundamental context, Pluang notes that Gilead Sciences reported strong earnings beats in both the first and second quarters of 2026, with results ahead of market expectations despite an overall negative net income margin of approximately -10.64% over the same period.
As summarized by GuruFocus, Gilead Sciences currently has trailing twelve months earnings per share of USD -2.66, reflecting the negative profitability, which makes traditional price-to-earnings valuation less meaningful and shifts investor attention to revenue growth and pipeline milestones.
The same valuation analysis from GuruFocus indicates that Gilead Sciences trades at a price-to-sales ratio of 6.05, significantly above its historical median of about 3.7 and also above the broader industry median, while the proprietary GF Value estimate stands at USD 106.55, implying that the stock is approximately 38.6% overvalued relative to that intrinsic value measure.
Dividend and analyst stance add nuances
Dividend income remains part of the Gilead Sciences stock story: Yahoo Finance reports that Gilead Sciences announced a cash dividend of USD 0.82 per share with an ex-dividend date of September 15, 2026, underlining the company’s continued practice of returning capital to shareholders even as it invests heavily in HIV and other therapeutic areas.
From the perspective of analyst consensus, INDmoney summarizes that, based on ratings from 21 analysts, around 80.95% currently recommend a Hold stance on Gilead Sciences stock, with a consensus target price of USD 158.15, representing an upside of 7.86% relative to a reference current price of USD 145.72 stated in the same overview.
On the shorter-term side, TradingView cites Zacks Research as keeping Gilead Sciences at a Rank 3, equivalent to Hold, after the new deal to expand lenacapavir access via the Pan American Health Organization, which suggests that while the licensing expansion is seen as positive for the pipeline, it has not yet shifted the overall risk-reward assessment decisively.
Risks and valuation tension around the HIV pipeline
Several analyses underscore that the current valuation already embeds substantial expectations for the future HIV prevention franchise. The GF Value framework described by GuruFocus flags Gilead Sciences stock as around 38.6% above its estimated intrinsic value, raising the risk that any delays, clinical setbacks or competitive pressure in the lenacapavir program could prompt a valuation reset.
At the same time, Simply Wall St notes that the partnership with the Pan American Health Organization to expand access to lenacapavir in 14 countries in Latin America and the Caribbean illustrates Gilead’s commitment to broad global reach, but also implies pricing and margin considerations as more of the lenacapavir business is channeled through regional purchasing systems rather than purely commercial markets.
For investors, the central tension in Gilead Sciences stock is therefore between the strong strategic positioning in HIV prevention, including once-yearly lenacapavir and twice-yearly formulations marketed as Yeztugo in the United States, and the current negative net income margin and valuation multiples that already price in substantial improvement in profitability and sustained growth.
Gilead Sciences stock price and trading snapshot
Gilead Sciences stock is listed on the Nasdaq under the ticker GILD. As of September 16, 2026, the shares were trading at USD 148.42 on the Nasdaq, up 1.45% on the day compared with the prior close of USD 146.30, with intraday levels reported between roughly USD 142.94 and USD 146.29 and a market capitalization of USD 181.54 billion based on data from MEXC and other price portals.
Key data on Gilead Sciences stock
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Nasdaq
- Price (as of September 16, 2026, 15:35): 148.42 USD
- Market capitalization: 181.54 billion USD (as of September 16, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
